Illumina, Inc. (ETR:ILU)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.11B +91.0% |
| Revenue (ttm) | 3.81B +1.3% |
| Net Income | 740.40M |
| EPS | 4.79 |
| Shares Out | n/a |
| PE Ratio | 28.51 |
| Forward PE | 29.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 243 |
| Open | 124.50 |
| Previous Close | 123.54 |
| Day's Range | 124.28 - 125.28 |
| 52-Week Range | 69.63 - 132.16 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
Integrated DNA Technologies enters collaboration with Illumina
Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library...
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
Illumina price target raised to $180 from $170 at Guggenheim
Guggenheim raised the firm’s price target on Illumina (ILMN) to $180 from $170 and keeps a Buy rating on the shares after having hosted the CFO and IR team for…
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN)...
Illumina announces new complete solution for MRD research
Illumina (ILMN) announced a new complete solution for molecular residual disease research based on whole-genome sequencing. As a distributed kit, it will enable more labs to adopt MRD detection for…
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's hi...
Illumina appoints David King to board of directors
Illumina (ILMN) confirmed the election of David King to its Board of Directors, effective immediately following the company’s annual meeting of shareholders. King’s election marks an important additio...
David P. King elected to Illumina's Board of Directors
Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed th...
Illumina Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals preliminarily approved. No questions were submitted during the Q&A, and forward-looking statements were qualified by reference to SEC filings.
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expandin...
Illumina resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Illumina (ILMN) with an Outperform rating and $170 price target The firm states that its constructive view on the stock is underpinned by building clinical…
Illumina upgraded to Outperform from Neutral at Daiwa
Daiwa upgraded Illumina (ILMN) to Outperform from Neutral with a $155 price target
What CEOs from Tesla, Nvidia and over a dozen other companies hope to gain by joining Trump in China
A key part of President Donald Trump's visit to China this week is his effort to bring along with him at least 17 executives from prominent U.S. companies. Here's what it means for them.
Illumina price target raised to $95 from $80 at Citi
Citi raised the firm’s price target on Illumina (ILMN) to $95 from $80 and keeps a Sell rating on the shares.
Illumina price target raised to $125 from $120 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Illumina (ILMN) to $125 from $120 and keeps a Neutral rating on the shares.
Illumina price target raised to $155 from $150 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Illumina (ILMN) to $155 from $150 and keeps an Outperform rating on the shares.
Illumina price target lowered to $140 from $150 at Canaccord
Canaccord lowered the firm’s price target on Illumina (ILMN) to $140 from $150 and keeps a Hold rating on the shares. The firm said the target decrease is driven by…
Illumina price target raised to $122 from $110 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $122 from $110 and keeps an Underweight rating on the shares. The company reported a big instrument upside surprise in…
Illumina Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong clinical growth and robust NovaSeq X demand, prompting raised full-year guidance for revenue, margin, and EPS. Clinical markets remain the primary growth driver, while research and applied markets are cautious amid funding uncertainty.
Illumina Earnings release: Q1 2026
Illumina released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Illumina Slides: Q1 2026
Illumina has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Illumina Quarterly report: Q1 2026
Illumina has published its Q1 2026 quarterly earnings report on April 30, 2026.
Illumina reports Q1 adjusted EPS $1.15, consensus $1.05
Reports Q1 revenue $1.09B, consensus $1.07B. “Illumina (ILMN) delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy,” said Jacob Thaysen, Ch...
Illumina raises FY26 adjusted EPS view to $5.15-$5.30 from $5.05-$5.20
FY26 consensus $5.12. Raises FY26 revenue view to $4.52B-$4.62B from $4.5B-$4.6B, consensus $4.54B.
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 202...